GAPI

First Generic Alternative to Eliquis® Now Available in Canada

Retrieved on: 
Monday, June 20, 2022
R, Apotex, Infarction, APO, API, BTL, Tablet, Stroke, GAPI, SVP, Patient, Ciba-Geigy Canada Ltd v Apotex Inc, CIBC World Markets, Commercial Operating System (COS), Anticoagulant, Risk, Generic drug, Birth control, Pharmaceutical industry, Apixaban, Aveva

TORONTO, June 20, 2022 /CNW/ - Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the launch of APO-ApixabanTM tablets, Canada's first generic alternative to Eliquis.

Key Points: 
  • TORONTO, June 20, 2022 /CNW/ - Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the launch of APO-ApixabanTM tablets, Canada's first generic alternative to Eliquis.
  • Apotex Inc. announced today the launch of APO-ApixabanTM tablets, Canada's first generic alternative to Eliquis.
  • Available in 2.5 mg and 5mg tablets, this product comes in multiple package sizes including 60, 180, and 500 BTL.
  • "It is with great pride that we launch APO-ApixabanTM," said Raymond Shelley, SVP, Commercial Operations, Canada & Rest of World Markets.

Apotex Launches Affordable Generic Option to Treat Relapsing Remitting Multiple Sclerosis

Retrieved on: 
Tuesday, May 17, 2022
API, Disease, R, RRMS, GAPI, Patient, Ciba-Geigy Canada Ltd v Apotex Inc, CIBC World Markets, MS, Commercial Operating System (COS), Multiple sclerosis, SVP, APO, Physical disability, Apotex, Health insurance, Generic drug, Sanofi, Aveva, Teriflunomide

TORONTO, May 17, 2022 /CNW/ - Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the Canadian launch of APO-Teriflunomidetablets, a generic version of Aubagio, for the treatment of relapsing remitting multiple sclerosis (RRMS).

Key Points: 
  • TORONTO, May 17, 2022 /CNW/ - Apotex Inc., Canada's leading pharmaceutical manufacturer of generic medicines, announced today the Canadian launch of APO-Teriflunomidetablets, a generic version of Aubagio, for the treatment of relapsing remitting multiple sclerosis (RRMS).
  • "We are pleased to provide Canada's multiple sclerosis patient community with a generic option of oral treatment, " said Raymond Shelley, SVP, Commercial Operations, Canada & Rest of World Markets.
  • Canada leads the world with one of the highest rates of multiple sclerosis, with an estimated 90,000 Canadians living with the disease.
  • Apotex Inc. is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world.

Canada-Wide Contest Recognizes the Impact of Pharmacy Professionals on Patient Care

Retrieved on: 
Tuesday, November 30, 2021
Patient, Senior, API, Pharmacy, CAD, R, Health, Ciba-Geigy Canada Ltd v Apotex Inc, GAPI, Apotex, Generic drug

TORONTO, Nov. 30, 2021 /CNW/ - To recognize the impact of Pharmacy Professionals on patient care in Canada, the country's largest domestic pharmaceutical manufacturer, Apotex Inc., announced today that it is now accepting nominations for the first-ever APOthecary Heroes Contest .

Key Points: 
  • TORONTO, Nov. 30, 2021 /CNW/ - To recognize the impact of Pharmacy Professionals on patient care in Canada, the country's largest domestic pharmaceutical manufacturer, Apotex Inc., announced today that it is now accepting nominations for the first-ever APOthecary Heroes Contest .
  • "As a Canadian-owned, Canadian-based company for close to 50 years, we have supported pharmacy success through multiple initiatives, donations, services and resources.
  • This unique contest is another way to demonstrate our gratitude for the role pharmacy professionals play in patient care."
  • Including but not limited to, consumers, patients, other pharmacy professionals and healthcare professionals.

Patient Access to Affordable Cancer Treatment Increases with the Launch of New Biosimilar in Canada

Retrieved on: 
Tuesday, November 9, 2021
Safety, GAPI, Bevacizumab, Apotex, General manager, R, Radiation, Infection, SVP, Ciba-Geigy Canada Ltd v Apotex Inc, Product, Partnership, Brain, G-CSF, Lung, Patient, Commercial Operating System (COS), API, Generic drug, Fine chemical, Pharmaceutical industry

Apobiologix's strategic partnership with Spanish-based biotechnology company mAbxience, supports the company's mission to transform access to affordable therapies in oncology and beyond.

Key Points: 
  • Apobiologix's strategic partnership with Spanish-based biotechnology company mAbxience, supports the company's mission to transform access to affordable therapies in oncology and beyond.
  • mAbxience has over a decade of experience in the development, manufacture and commercialization of biopharmaceutical medicines.
  • Apobiologix launched its first product, Grastofil(filgrastim), in Canada in2016, followed by the launch of Lapelga(pegfilgrastim) in 2019, the first-ever pegfilgrastim biosimilar approved in any highly regulated market.
  • "We look forward to further expansion of the Apobiologix portfolio to ensure we continue to support patient needs."

CloudMD Partners with Apotex Latinoamérica to Drive Expansion of Health Educational Resources Across the Region

Retrieved on: 
Wednesday, November 3, 2021
Technology, Ecosystem, Medical assistant, Partnership, Database, Patient, General manager, Apotex, Language, Telehealth, Anatomy, Ciba-Geigy Canada Ltd v Apotex Inc, Company, IMD, OTC, CEO, GAPI, Ontario Student Assistance Program, API, Health, Artificial intelligence, R, GLOBE, Center for Pan Asian Community Services, Inc., Student, Medicine, Generic drug

Together, CloudMD and Apotex Latinoamrica have partnered to provide better access to healthcare resources for doctors and patients in Latin America.

Key Points: 
  • Together, CloudMD and Apotex Latinoamrica have partnered to provide better access to healthcare resources for doctors and patients in Latin America.
  • CloudMDs educational platform will provide access to trusted, peer-reviewed healthcare resources that will assist and support doctors and patients throughout their care journey.
  • Our Partnership with CloudMD to adopt its IMD Health education platform reinforces our commitment to provide trusted healthcare resources to support and educate individuals through their health journeys.
  • Dr. Essam Hamza, CEO of CloudMD commented, We are excited to announce an expansion of our partnership with Apotex into Latin America.

Voluntary Nationwide Recall: One Lot of Mirvala™ 28 (desogestrel and Ethinyl Estradiol Tablets, Usp) 0.150 Mg / 0.030 Mg Due to Possibility of One Placebo Pill in Place of An Active Pill

Retrieved on: 
Thursday, September 30, 2021
Tablet, USP, List of combined sex-hormonal preparations, Patient, Pharmacy, Ciba-Geigy Canada Ltd v Apotex Inc, API, Apotex, Blister, Desogestrel, Letter, GAPI, Ethinylestradiol, Medication, Stericycle, R, Generic drug

Mirvala 28 (Desogestrel and Ethinyl Estradiol Tablets, USP 0.150 mg / 0.030 mg) is indicated for conception control.

Key Points: 
  • Mirvala 28 (Desogestrel and Ethinyl Estradiol Tablets, USP 0.150 mg / 0.030 mg) is indicated for conception control.
  • The product is packaged as 28 tablets in a blister packet.
  • The impacted lot was distributed nationwide in Canada to wholesalers, distributors and pharmacies by Apotex between December 08, 2020 and August 24, 2021.
  • Patients who have received the impacted lot of Mirvala 28 (Desogestrel and Ethinyl Estradiol Tablets, USP 0.150 mg / 0.030 mg) should return the product to a pharmacy for replacement.

Canadian-Made Generic Option to Treat Multiple Myeloma Now Available

Retrieved on: 
Wednesday, September 1, 2021
Ciba-Geigy Canada Ltd v Apotex Inc, GAPI, Lenalidomide, World Marketing Summit, Multiple myeloma, Apotex, Immune system, Myelodysplastic syndrome, R, SVP, Patient, Health Canada, Commercial, API, Health insurance, Generic drug

TORONTO, Sept. 1, 2021 /CNW/ -Today, Canada's largest pharmaceutical manufacturer, Apotex Inc., announced the Canadian launch of the generic version of Revlimid capsules, APO-lenalidomide for the treatment of multiple myeloma and Myelodysplastic syndrome.

Key Points: 
  • TORONTO, Sept. 1, 2021 /CNW/ -Today, Canada's largest pharmaceutical manufacturer, Apotex Inc., announced the Canadian launch of the generic version of Revlimid capsules, APO-lenalidomide for the treatment of multiple myeloma and Myelodysplastic syndrome.
  • Lenalidomide targets and kills myeloma cells directly and stimulates the immune system to do the same.
  • "Generics play an important role in the Canadian healthcare system, as generics can help payers redirect funds to newer therapies and general patient care."
  • Generic lenalidomide can deliver much-needed cost savings for the Canadian healthcare system, approximately saving between $220-$360 million dollars per year.